Medical Oncologists' Knowledge and Perspectives on the Use of Biosimilars in the United States
- 1 March 2023
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (3) , e457-e464
Abstract
PURPOSE: Despite increasing availability of biosimilar cancer treatments, little is known about oncologists' knowledge and concerns regarding biosimilar use in the United States. We surveyed medical oncologists to examine their knowledge, attitudes, and experience with biosimilars. METHODS: Oncologists recruited via the ASCO Research Survey Pool completed a 29-question survey in 2020 designed with input from clinical and health care system experts and literature review. RESULTS: Of the 269 respondents, most treated patients with biosimilars (n = 236, 88%) and reported that biosimilars were required at their institution (n = 168, 63%). Approximately half (n = 140, 52%) of oncologists correctly responded that biosimilars were not the same as generic medicines. Commonly reported barriers to use of biosimilars included concerns regarding a perceived lack of relevant research (n = 85, 33% reporting quite a bit/very much), the potential for extrapolation (n = 83, 33%), and efficacy limitations (n = 77, 30%). More oncologists from university hospitals (n = 36, 22%) than from community/private hospitals (n = 28, 38%) or private practices (n = 13, 38%) were concerned about biosimilar efficacy. A high proportion of oncologists reported that information on safety (n = 259, 99%) and efficacy (n = 255, 99%) is important when considering whether to use biosimilars. Less than half reported that their institution provided education about biosimilars (n = 108, 40%). CONCLUSION: In this sample of medical oncologists, knowledge about basic features of biosimilars was limited and access to information about biosimilars was insufficient. The present study determined that educational programs on biosimilars for oncologists are needed and identified priorities for such efforts.Keywords
This publication has 8 references indexed in Scilit:
- Physicians’ perceptions of the uptake of biosimilars: a systematic reviewBMJ Open, 2020
- Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and CanadaThe Oncologist, 2019
- Evaluation of Physicians’ Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their PrescribingBiomolecules, 2019
- Academic oncology clinicians’ understanding of biosimilars and information needed before prescribingTherapeutic Advances in Medical Oncology, 2019
- Barriers to Oncology Biosimilars Uptake in the United StatesThe Oncologist, 2018
- American Society of Clinical Oncology Statement: Biosimilars in OncologyJournal of Clinical Oncology, 2018
- Biosimilars in Oncology in the United StatesJAMA Oncology, 2018
- Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty PhysiciansAdvances in Therapy, 2016